Literature DB >> 25834501

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Yan Zhang1, Chunxia Qiao2, Lian Li3, Xuye Zhao4, Yali Li1.   

Abstract

OBJECTIVE: This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign gynecological disorders.
MATERIAL AND METHODS: Sera were obtained from Chinese women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with HE4 and CA125 levels were compared.
RESULTS: There were 68 Chinese women with benign diseases. HE4 levels were less elevated than CA125 (1% V.S. 29%, P<0.001). The significant difference was observed in patients with endometriosis/endometriomas in which HE4 was not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with cystadenoma (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001).
CONCLUSION: HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.

Entities:  

Keywords:  CA125; HE4; benign gynecological disease; biomarker

Mesh:

Substances:

Year:  2014        PMID: 25834501      PMCID: PMC4370071          DOI: 10.4314/ahs.v14i4.20

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  30 in total

1.  CA125 production by the peritoneum: in-vitro and in-vivo studies.

Authors:  M Epiney; C Bertossa; A Weil; A Campana; P Bischof
Journal:  Hum Reprod       Date:  2000-06       Impact factor: 6.918

2.  Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women.

Authors:  M Hallamaa; P Suvitie; K Huhtinen; J Matomäki; M Poutanen; A Perheentupa
Journal:  Gynecol Oncol       Date:  2012-03-14       Impact factor: 5.482

3.  Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.

Authors:  Kevin Holcomb; Zivjena Vucetic; M Craig Miller; Robert C Knapp
Journal:  Am J Obstet Gynecol       Date:  2011-05-14       Impact factor: 8.661

4.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.

Authors:  C Kirchhoff; I Habben; R Ivell; N Krull
Journal:  Biol Reprod       Date:  1991-08       Impact factor: 4.285

5.  Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.

Authors:  Craig C Earle; Deborah Schrag; Bridget A Neville; K Robin Yabroff; Marie Topor; Angela Fahey; Edward L Trimble; Diane C Bodurka; Robert E Bristow; Michael Carney; Joan L Warren
Journal:  J Natl Cancer Inst       Date:  2006-02-01       Impact factor: 13.506

6.  Pelvic mass associated with raised CA 125 for benign condition: a case report.

Authors:  Viren Asher; Robert Hammond; Tim J Duncan
Journal:  World J Surg Oncol       Date:  2010-04-16       Impact factor: 2.754

7.  [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Authors:  Li Dong; Xiao-Hong Chang; Xue Ye; Li-Rong Zhu; Yang Zhao; Li Tian; Hong-Yan Cheng; Xiao-Ping Li; Hong Zhang; Qin-Ping Liao; Tian-Yun Fu; Ye-Xia Cheng; Heng Cui
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2008-12

8.  Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival.

Authors:  R E Buller; M L Berman; J D Bloss; A Manetta; P J DiSaia
Journal:  Gynecol Oncol       Date:  1992-10       Impact factor: 5.482

9.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

10.  Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Authors:  Elham O Hamed; Hydi Ahmed; Osama B Sedeek; Abeer M Mohammed; Ali A Abd-Alla; Hazem M Abdel Ghaffar
Journal:  Diagn Pathol       Date:  2013-01-23       Impact factor: 2.644

View more
  3 in total

1.  Editorial.

Authors:  James Tumwine
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

2.  Level of HE4 is Correlated with Diagnosis of Struma Ovarii: A Case Report.

Authors:  Stavros Diavatis; Alexis Papanikolaou
Journal:  Am J Case Rep       Date:  2016-07-06

3.  Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.

Authors:  Fenfen Zhang; Yao Liu; Quan Quan; Yu Meng; Xiaoling Mu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.